Day: October 28, 2020

MADISON, Wis., Oct. 28, 2020 (GLOBE NEWSWIRE) — Mediasite Events today announces a new complete virtual event platform for a video-first world. No two events are the same, and the Mediasite Events team is custom-building virtual worlds for organizations and schools of all sizes for a flexible, scalable and engaging experience, despite distance.  The team, which has more than 15 years of experience creating dynamic online events all over the globe, is providing white glove services without the need for travel. The virtual event platform includes everything from a customizable event website with live or simulated live session streaming, content catalogues, e-commerce options for sponsors, virtual expo halls, e-poster sessions, interactive features like live chat and polling and more.  “Our new virtual event platform is everything you...

BURLINGAME, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the Phase 1/2 ASPEN-02 study evaluating the combination of ALX148, a next-generation CD47 blocker, with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome (“MDS”).The Phase 1 part of the study is expected to characterize the safety of ALX148 in combination with azacitidine in patients with relapsed/refractory or previously untreated higher-risk MDS. Upon completion of the Phase 1, the Phase 2 component of the study will be initiated to evaluate the efficacy of the combination in patients with previously untreated higher-risk MDS.This...

PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease (RPD) designations to PBKR03 for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). Passage Bio expects to initiate a Phase 1/2 trial for PBKR03 in the first half of 2021. Krabbe disease is a rare and often life-threatening lysosomal storage disease that presents early in the patient’s life, resulting in progressive damage to both the brain and peripheral nervous system.“Receiving both Orphan Drug and Rare Pediatric Disease designations for PBKR03 underscore the urgent unmet medical need for children...

TROY, Mich., Oct. 28, 2020 (GLOBE NEWSWIRE) — Altair, (Nasdaq: ALTR) a global technology company providing solutions in data analytics, simulation, and high-performance computing (HPC), today announced the launch of the Altair Material Data Center, a modern, comprehensive, and high-fidelity material database for simulation. The Altair Material Data Center includes accurate data and data lineage for metals, plastics, and composites, and directly connects with Altair’s and other major solvers.One of the most important decisions in product development is the selection of materials for production. Altair has been investing significantly in the area of material modeling for several years and recently acquired M-Base, a leading international supplier of material database and material information systems with a focus on plastics.The launch...

RIDGEFIELD, Conn., Oct. 28, 2020 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States and Canada, today reported financial results for its third quarter ended September 25, 2020.Financial highlights for the third quarter of 2020:Net sales decreased 36.0% to $254.0 million for the third quarter of 2020 from $396.9 million for the third quarter of 2019.GAAP net loss was $11.4 million, or $(0.31) per diluted share, for the third quarter of 2020 compared to net income of $4.4 million, or $0.15 per diluted share, in the third quarter of 2019.Adjusted EPS1 was $(0.38) for the third quarter of 2020 compared to $0.23 for the third quarter of 2019.Adjusted EBITDA1 was $(4.9) million for the third quarter of 2020 compared to $21.6 million...

VANCOUVER, British Columbia, Oct. 28, 2020 (GLOBE NEWSWIRE) — Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (the “Company” or “Calibre”) will release its third quarter 2020 financial results on Wednesday, November 4, 2020 after the market close. Management will host a conference call and webcast to discuss the results on Thursday, November 5, 2020 at 10:00 a.m. (EDT). Conference call and webcast details as follows:Presentation slides which accompany the conference call can be accessed at www.calibremining.com under Investors and Presentations section of the Calibre website (link here).About Calibre Mining Corp.Calibre Mining is a Canadian-listed gold mining and exploration company with two 100%-owned operating gold mines in Nicaragua. The Company is focused on sustainable operating performance and a disciplined approach to growth....

YAVNE, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has completed the enrollment stage of its NexoBrid® Phase 3 pediatric clinical study (CIDS – Children Innovation Debridement Study). Top-line results with 12 months follow up data anticipated during the second half of 2021. Additionally, the completion of the CIDS enrollment stage follows the U.S. Food and Drug Administration (FDA)’s recent agreement to allow the NexoBrid expanded access (NEXT) protocol to be expanded to include pediatric as well as adult burn patients.“We are pleased to complete the enrollment stage of our NexoBrid pediatric Phase 3 study, which is one of the most comprehensive...

Piraeus, Greece, Oct. 28, 2020 (GLOBE NEWSWIRE) — GasLog Ltd. (“GasLog”) (NYSE: GLOG) and GasLog Partners LP (“GasLog Partners” or the “Partnership”) (NYSE: GLOP) today announced that their financial results for the third quarter of 2020 will be released before the market opens on Tuesday, November 10, 2020.GasLog and GasLog Partners will host a joint conference call to discuss their results for the third quarter of 2020 at 8.30 a.m. EST (3.30 p.m. EET) on Tuesday, November 10, 2020. Senior management of GasLog and GasLog Partners will review the operational and financial performance of both companies. The presentation of each company’s third quarter results will be followed by separate Q&A sessions for each company.The dial-in numbers for the conference call are as follows:+1 855 253 8928...

Piraeus, Greece, Oct. 28, 2020 (GLOBE NEWSWIRE) — GasLog Ltd. (“GasLog”) (NYSE: GLOG) and GasLog Partners LP (“GasLog Partners” or the “Partnership”) (NYSE: GLOP) today announced that their financial results for the third quarter of 2020 will be released before the market opens on Tuesday, November 10, 2020.GasLog and GasLog Partners will host a joint conference call to discuss their results for the third quarter of 2020 at 8.30 a.m. EST (3.30 p.m. EET) on Tuesday, November 10, 2020. Senior management of GasLog and GasLog Partners will review the operational and financial performance of both companies. The presentation of each company’s third quarter results will be followed by separate Q&A sessions for each company.The dial-in numbers for the conference call are as follows:+1 855 253 8928...

RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts and one Distinguished Industry Oral Abstract at the upcoming Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) November 13-15, which is being conducted as a virtual meeting.Berotralstat Reduces Attacks in Patients with Hereditary Angioedema (HAE): APeX-2 Trial 48 Week Results; Distinguished Industry Oral Abstract, Session A, Friday, November 13, 4:30-5:30 p.m. CTBerotralstat Improves Patient-Reported Quality of Life Through 48 Weeks in the Phase 3 APeX-2 Trial; Poster #154Berotralstat Positively Impacts Patient-Reported Satisfaction: Results from the Phase 3 APeX-2 trial; Poster #158Patient Perspectives on the Treatment...